November 5-7, 2018
Copenhagen, Denmark
News
- Aplagon Partners with Cadila Pharmaceuticals to Develop and Commercialize APAC First-in-Class Antithrombotics for the Prevention of Blood Vessel Occlusions Related to Vascular Interventions 19 September 2017 - HELSINKI AND STOCKHOLM, September 19, 2017. Aplagon Oy (“Aplagon”) and Cadila Pharmaceuticals Sweden AB today announced a development and commercialization agreement for Aplagon’s lead APAC product. APACs are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury. Under the agreement, Cadila Pharmaceuticals Sweden AB together with its… read more »
Events
Aplagon will be represented at the following partnering or scientific meetings.
- Bio-Europe 2018